Heart failure articles from across Nature Portfolio

Glatiramer acetate, a drug with an established history of treating multiple sclerosis in clinical practice, improves cardiac function in rodent models of myocardial infarction and ischemic heart failure.

Yu Shi et al. show that the citric acid cycle metabolite α-ketoglutarate promotes cardiomyocyte proliferation during heart development and promotes heart regeneration after myocardial infarction.

This participant-level pooled analysis of the three phase III trials that have tested the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes provides an integrated view of the mortality, cardiovascular and renal effects of this treatment. Editor recognition statement: Primary Handling editor: Michael Basson, in collaboration with the Nature Medicine team.

In a multicenter, open-label, randomized controlled trial, digital consults including digital data sharing, patient e-learning and guideline recommendations to clinicians improved guideline-directed medical therapy over the course of 12 weeks.

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) remains poorly understood. In this Review, Redfield and colleagues highlight the importance of studying human cardiac tissue in HFpEF, discuss sources, challenges and methods for studying human myocardial samples, summarize pathophysiological insights derived from studies of human myocardium in HFpEF and outline knowledge gaps to guide future research.

Cardiomyocytes are the dominant initiators of a type I interferon response in the infarct borderzone.

Glatiramer acetate, a drug with an established history of treating multiple sclerosis in clinical practice, improves cardiac function in rodent models of myocardial infarction and ischemic heart failure.

A large clinical trial supports the incorporation of qiliqiangxin, a traditional Chinese medicine, into standard treatment regimens for heart failure — highlighting a promising integration of ancient wisdom with modern medical practices through rigorous science.

A new small-molecule inhibitor of vasohibins reduces myocardial stiffness and improves diastolic relaxation in a rat model of HFpEF.

For patients with shortness of breath, a new, simplified screening tool — relying only on basic clinical information — can estimate the probability of heart failure with preserved ejection fraction, providing the opportunity for improved detection in non-specialist settings.

In an observational cohort study of adults living with obesity and diabetes, we found that the primary incidence of congestive heart failure was lower in patients treated with bariatric metabolic surgery than in those on first-generation GLP-1 receptor agonists, an effect that was not explained by greater weight loss in the group that received bariatric metabolic surgery.

Myofibroblast activation requires nuclear translocation of ATP citrate lyase (ACLY) that triggers chromatin remodeling and the induction of fibrosis-associated genes. ACLY inhibition prevents myofibroblast conversion and causes de-differentiation of myofibroblasts to fibroblasts, indicating a potential therapeutic approach for heart failure.